spacer
  Home | About CDC | Press Room | Funding | A-Z Index | Centers, Institute & Offices | Training & Employment | Contact Us
spacer
spacer CDC Centers for Disease Control and Prevention Home Page spacer
CDC en Español
spacer
 
spacer
Health & Safety TopicsPublications & ProductsData & StatisticsConferences & Events
spacer
spacer
spacer
spacer
  CLIA Content
space
arrow CLIA
space
arrow Chronology
space
arrow Complexities
space
arrow Demographics
space
arrow CLIA Law
space
arrow Regulations
space

  Related Content
space
arrow DLS Home
space
arrow Genetics
space
arrow International
space
arrow IQLM
space
arrow MASTER
space
arrow MPEP
space
arrow NLTN
space
arrow Publications
space
arrow Training
space
spacer spacer
spacer
spacer

Agreement Between Cytopathologists Referencing Glass
Slides for Gynecologic Proficiency Testing
  - Gagnon MC, Kurtycz D, Collins CL

Abstract

In order to help implement the cytology proficiency testing (PT) requirements of the Clinical Laboratory Improvement Amendment of 1988 (CLIA), the Centers for Disease Control and Prevention (CDC) collected and referenced approximately 1500 cervical cytology slides in six months. Referencing of the glass slides included stratification into the four CLIA categories and obtaining consensus by three pathologists.

Slides were first screened by cytotechnologists blinded from the diagnosis of the contributing laboratory. If the original diagnosis did not match the diagnosis given by the cytotechnologists, the slides were eliminated. Three cytopathologists then looked at the slides and either agreed or disagreed with the diagnosis. The cytopathologists were also asked to identify slides that were unsuitable for proficiency testing.

Cytotechnologists eliminated 33% of the slides from further review (26% did not match the original diagnosis and 7% were considered poor quality). The cytopathologists reviewed the remaining 947 slides, with 756 receiving final diagnostic consensus.

Slides in the categories for unsatisfactory and low grade squamous intraepithelial lesions (LG-SIL) were the hardest to achieve consensus. It was anticipated that it would be difficult to obtain consensus of the unsatisfactory category since the professional community has not reached agreement on the criteria for unsatisfactory. The difficulty in achieving consensus on slides in the LG-SIL was not anticipated. There was a tendency for our evaluators to either overcall or undercall the low grade lesions.

Introduction

In December 1987, the Wall Street Journal published a series of articles about problems with the evaluation of pap smears. It reported "cases of cancer missed due to excessive workloads of cytotechnologists, lack of quality control procedures, and poorly educated personnel". The articles were followed by a televised report of poor quality control and a lack of government regulations. This media attention prompted congressional hearings that led to the passage of the Clinical Laboratory Improvement Amendments of 1988 (CLIA). CLIA directed the Secretary of Health and Human Services (HHS) to establish individual workload limits for a 24 hour period; to establish quality control measures; to set personnel standards; and to provide for annual proficiency testing of cytotechnologists and pathologists.

The regulations for implementing CLIA were published in the Federal Register of February 28, 1992. The regulations described the program content of a cytology PT to include 10 and 20 glass slide tests comprised of at least one challenge from each of the four diagnostic categories extracted from the Bethesda system. The use of glass slides was written into the regulation to fulfill the statutory requirement "under normal working conditions".

To date there is one state PT program, Maryland that meets the CLIA criteria. HHS still has the responsibility to implement PT for the large number of cytotechnologists and pathologists who are currently not being tested. In this ongoing effort to promote the development of PT programs, CDC complied a collection of glass slides that have been reviewed by three pathologists and have consensus in one of the four diagnostic categories.

METHODS

A request for proposals (RFP) to solicit the purchase of gynecologic cytology slides for proficiency testing, self assessment, and training was sent out on May 19, 1994. This RFP provided a total of 1500 slides.

Demographic information from each slide was entered in a database. The database allowed us to track the slides through the review process and to print reports that facilitated the review.

The first step in the process was an initial screening of the 1500 slides by cytotechnologists. This was accomplished through an agreement with the American Society for Cytotechnology (ASCT). A total of eleven cytotechnologists took part in this initial screening which took place at CDC on two separate dates. The cytotechnologists who screened the slides were blinded from the original diagnosis obtained from the contributing laboratory. The cytotechnologists dotted significant cells on the slides and placed them in to one of the four diagnostic categories identified in CLIA. The Cytotechnologists Review Form is shown in Figure 1. The diagnosis obtained from the cytotechnologists review was compared to the contributing laboratories diagnosis. If the contributing laboratories diagnosis did not match with the diagnosis given by the cytotechnologists, the slides were eliminated from further review.

The remaining slides were then reviewed by pathologists. A total of thirteen pathologists were used in the three review sessions that also took place at CDC. Three pathologists looked at each slide and either agreed or disagreed with the diagnosis. The form for this step is shown in Figure 2. The pathologists were also asked to make comments and to identify slides that were not suitable for PT.

RESULTS

A total of 1500 slides were included in the review, 756 (50%) slides met consensus for one of the four diagnostic categories. The cytotechnologists eliminated 497 (33)% of the slides. Of the 33%, 460 were eliminated when the diagnosis of the cytotechnologists did not match that of the contributing laboratories and 37 were eliminated due to poor quality (IE., needed recoverslipping, stain was not optimal, or was thought to be problematic as a PT slide). In addition 77 (5%) of the slides were returned to the original laboratory at the request of the laboratory. Figure 3 contains a list of the referencing descriptions applied to the slides.

Of the 1500 slides the diagnosis from the contributing laboratories indicated 200 slides were from the A category, 689 slides were from the B category, 302 slides were from the C category and 308 slides were from the D category. The slides are identified by categories in Figure 4 . Consensus was obtained on 34% of the slides in category A, 59% of the slides in category B, 29% of the slides in category C and 66% of the slides in category D.

The pathologists reviewed 947 slides with 756 (80%) receiving full consensus. Since most of the slides were eliminated in the blind review this meant the pathologists elimnated an additional 12% of the total slides.

Of the 947 slides reviewed by the pathologist consensus was obtained in 60% of the slides in category A, 87% of the slides in category B, 45% of the slides in category C, and 90% of the slides in category D. The results of the pathologists review is shown in Figure 5. Slides that did not receive consensus were diverted to the training branch and will be used to produce training materials that will be distributed through the National Laboratory Training Network.

The intent of the stringent review process was to obtain slides that are fair and equitable for testing. Inter-observer variability makes the process difficult. In particular it was hard to achieve consensus of the category A and C slides. There is still disagreement on what constitutes an unsatisfactory slide and how to apply the 10% and 25% acceptability rules. The most surprising finding was the amount of disagreement between our pathologist for LG-SIL. Cases were often undercalled to ASCUS or overcalled the HG-SIL.

National testing and training efforts can help standardize the diagnostic features used by the different laboratories and eliminate the problems associated with inter-observer variability.

REFERENCES:

  1. Public Law 100-578, The Clinical Laboratory Improvement Amendments of 1988, October 31, 1988.
  2. HSQ-176-FC; 57 FR 7002, February 28, 1992.
  3. Kurman, Robert J. and Solomon, Diane, The Bethesda System, Springer-Verlag, New York (1994).

This page last reviewed: 7/7/2004
spacer
spacer
spacer
spacer
  Home | Policies and Regulations | Disclaimer | e-Government | FOIA | Contact Us
spacer
spacer
spacer Safer, Healthier People
spacer
Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, U.S.A
Tel: (404) 639-3311 / Public Inquiries: (404) 639-3534 / (800) 311-3435
spacer FirstGovDHHS Department of Health
and Human Services